FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103576304> ?p ?o ?g. }

• W2103576304 endingPage "1995" @default.
• W2103576304 startingPage "1992" @default.
• W2103576304 abstract "No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Dec 2000ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER C. PALMBERG, P. KOIVISTO, L. KAKKOLA, T.L.J. TAMMELA, O.P. KALLIONIEMI, and T. VISAKORPI C. PALMBERGC. PALMBERG More articles by this author , P. KOIVISTOP. KOIVISTO More articles by this author , L. KAKKOLAL. KAKKOLA More articles by this author , T.L.J. TAMMELAT.L.J. TAMMELA More articles by this author , O.P. KALLIONIEMIO.P. KALLIONIEMI More articles by this author , and T. VISAKORPIT. VISAKORPI More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)66935-2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Amplification of the androgen receptor gene has been found in a third of hormone refractory prostate carcinomas. It is possible that amplification facilitates cell growth ability in low concentrations of androgens remaining in the serum after androgen deprivation therapy. We evaluate whether androgen receptor gene amplification at primary progression is associated with response to second line combined androgen blockade for prostate cancer. Materials and Methods: A total of 77 patients with prostate cancer were treated initially with androgen deprivation monotherapy followed by combined androgen blockade after the first progression. After initiation of second line combined androgen blockade patients were followed every 3 months to evaluate treatment responses. Biopsies were taken from the prostate at the first progression under endocrine monotherapy. Androgen receptor gene copy number was determined by fluorescence in situ hybridization. Results: Androgen receptor gene amplification was found in 10 of the 77 cases (13%) at the primary disease progression, and was associated with a favorable response to second line combined androgen blockade. Only 1 of 34 (3%) patients classified as nonresponders had androgen receptor gene amplification, whereas 9 of 41 (21%) classified as having either stable disease or response had amplification (p = 0.016). Patients with androgen receptor gene amplification also had a decrease in prostate specific antigen more often after combined androgen blockade than those with no amplification (p = 0.079). However, androgen receptor gene amplification was not associated with patient survival after the first progression. Conclusions: Androgen receptor gene amplification detected in tumors progressing during androgen deprivation monotherapy is associated with favorable treatment response to second line combined androgen blockade. This finding suggests that at least some androgen receptor amplified tumors retain a high degree of dependency on residual androgens remaining in serum after monotherapy. References 1 : SEER Cancer Statistics Review, 1973–1992: Tables and Graphs. National Cancer Institute. Bethesda, MD: U.S. Department of Health and Human Services1996. NIH Pub. No. 96-2789. Google Scholar 2 Finnish Cancer Registry: Cancer Incidence in Finland 1995. Cancer Society of Finland, Pub. No. 58, Helsinki 1997 Google Scholar 3 : Carcinoma of the prostate. Hormonal therapy. Cancer1987; 60: 589. Google Scholar 4 : Hormone refractory disease. Semin Surg Oncol1995; 11: 77. Google Scholar 5 : PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol1999; 36: 191. Google Scholar 6 : Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer. J Steroid Biochem1986; 25: 877. Google Scholar 7 : Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience. Cancer Metastasis Rev1987; 6: 615. Google Scholar 8 : Combined androgen blockade for the treatment of metastatic cancer of the prostate. Urology1996; 47: 622. Google Scholar 9 : A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med1989; 321: 419. Google Scholar 10 : Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med1998; 339: 1036. Google Scholar 11 Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists’ Collaborative Group. Lancet1995; 346: 265. Google Scholar 12 : Benefits of combination therapy with flutamide in patients relapsing after castration. Br J Urol1988; 61: 341. Google Scholar 13 : Adrenal androgen blockade in relapsed prostate cancer. Eur J Cancer Clin Oncol1985; 21: 1127. Google Scholar 14 : In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet1995; 9: 401. Google Scholar 15 : Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res1997; 57: 314. Google Scholar 16 : Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res1999; 59: 803. Google Scholar 17 : Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol1997; 31: 216. Google Scholar 18 : TNM-Classification of Malignant Tumours. New York: Springer-Verlag1992. Google Scholar 19 : International Histologic Classification of Tumours1980; . Google Scholar 20 : Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. Cytometry1994; 16: 93. Google Scholar 21 : BMDP Statistical Software. Berkeley, Los Angeles. London: University of California Press1981. Google Scholar 22 : Experience with flutamide in advanced prostatic cancer patients refractory to previous endocrine therapy. J Drug Dev1987; 1: 10. Google Scholar 23 : Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. J Urol1998; 159: 1606. Link, Google Scholar 24 : Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. J Urol1999; 161: 1070. Link, Google Scholar 25 : Identification of bone marrow micrometastases in patients with prostate cancer. Cancer1994; 74: 2533. Google Scholar 26 : Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res1999; 59: 2511. Google Scholar 27 : Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res1994; 54: 5474. Google Scholar 28 : A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med1999; 5: 280. Google Scholar From the Division of Urology, Tampere University Hospital, Laboratory of Cancer Genetics, Institute of Medical Technology and University of Tampere, Tampere, Finland© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited bySuzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T and Miki T (2018) Alternative Nonsteroidal Antiandrogen Therapy for Advanced Prostate Cancer That Relapsed After Initial Maximum Androgen BlockadeJournal of Urology, VOL. 180, NO. 3, (921-927), Online publication date: 1-Sep-2008.KOJIMA S, SUZUKI H, AKAKURA K, SHIMBO M, ICHIKAWA T and ITO H (2018) Alternative Antiandrogens to Treat Prostate Cancer Relapse After Initial Hormone TherapyJournal of Urology, VOL. 171, NO. 2, (679-683), Online publication date: 1-Feb-2004.KASPER S and SMITH J (2018) GENETICALLY MODIFIED MICE AND THEIR USE IN DEVELOPING THERAPEUTIC STRATEGIES FOR PROSTATE CANCERJournal of Urology, VOL. 172, NO. 1, (12-19), Online publication date: 1-Jul-2004.CULIG Z, KLOCKER H, BARTSCH G, STEINER H and HOBISCH A (2018) Androgen Receptors in Prostate CancerJournal of Urology, VOL. 170, NO. 4 Part 1, (1363-1369), Online publication date: 1-Oct-2003.FORD O, GREGORY C, KIM D, SMITHERMAN A and MOHLER J (2018) Androgen Receptor Gene Amplification and Protein Expression in Recurrent Prostate CancerJournal of Urology, VOL. 170, NO. 5, (1817-1821), Online publication date: 1-Nov-2003. Volume 164Issue 6December 2000Page: 1992-1995 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.KeywordshormonesendocrinologyprostatetherapeuticsMetricsAuthor Information C. PALMBERG More articles by this author P. KOIVISTO More articles by this author L. KAKKOLA More articles by this author T.L.J. TAMMELA More articles by this author O.P. KALLIONIEMI More articles by this author T. VISAKORPI More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2103576304 created "2016-06-24" @default.
• W2103576304 creator A5042803923 @default.
• W2103576304 creator A5050670008 @default.
• W2103576304 creator A5077371642 @default.
• W2103576304 creator A5082556049 @default.
• W2103576304 creator A5085775392 @default.
• W2103576304 creator A5086949891 @default.
• W2103576304 date "2000-12-01" @default.
• W2103576304 modified "2023-10-18" @default.
• W2103576304 title "ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER" @default.
• W2103576304 cites W1580523172 @default.
• W2103576304 cites W1970735557 @default.
• W2103576304 cites W1974518923 @default.
• W2103576304 cites W1980851683 @default.
• W2103576304 cites W1992513803 @default.
• W2103576304 cites W1998726940 @default.
• W2103576304 cites W2003985632 @default.
• W2103576304 cites W2010713397 @default.
• W2103576304 cites W2011255111 @default.
• W2103576304 cites W2011580644 @default.
• W2103576304 cites W2014145760 @default.
• W2103576304 cites W2022635468 @default.
• W2103576304 cites W2068504016 @default.
• W2103576304 cites W2090516977 @default.
• W2103576304 cites W2121341625 @default.
• W2103576304 cites W2617245288 @default.
• W2103576304 cites W4248502584 @default.
• W2103576304 cites W79483553 @default.
• W2103576304 doi "https://doi.org/10.1016/s0022-5347(05)66935-2" @default.
• W2103576304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11061898" @default.
• W2103576304 hasPublicationYear "2000" @default.
• W2103576304 type Work @default.
• W2103576304 sameAs 2103576304 @default.
• W2103576304 citedByCount "144" @default.
• W2103576304 countsByYear W21035763042012 @default.
• W2103576304 countsByYear W21035763042013 @default.
• W2103576304 countsByYear W21035763042014 @default.
• W2103576304 countsByYear W21035763042015 @default.
• W2103576304 countsByYear W21035763042016 @default.
• W2103576304 countsByYear W21035763042017 @default.
• W2103576304 countsByYear W21035763042018 @default.
• W2103576304 countsByYear W21035763042019 @default.
• W2103576304 countsByYear W21035763042020 @default.
• W2103576304 countsByYear W21035763042021 @default.
• W2103576304 countsByYear W21035763042022 @default.
• W2103576304 countsByYear W21035763042023 @default.
• W2103576304 crossrefType "journal-article" @default.
• W2103576304 hasAuthorship W2103576304A5042803923 @default.
• W2103576304 hasAuthorship W2103576304A5050670008 @default.
• W2103576304 hasAuthorship W2103576304A5077371642 @default.
• W2103576304 hasAuthorship W2103576304A5082556049 @default.
• W2103576304 hasAuthorship W2103576304A5085775392 @default.
• W2103576304 hasAuthorship W2103576304A5086949891 @default.
• W2103576304 hasConcept C121608353 @default.
• W2103576304 hasConcept C126322002 @default.
• W2103576304 hasConcept C126894567 @default.
• W2103576304 hasConcept C143998085 @default.
• W2103576304 hasConcept C170493617 @default.
• W2103576304 hasConcept C2776235491 @default.
• W2103576304 hasConcept C2777911890 @default.
• W2103576304 hasConcept C2778468042 @default.
• W2103576304 hasConcept C2780192828 @default.
• W2103576304 hasConcept C502942594 @default.
• W2103576304 hasConcept C61367390 @default.
• W2103576304 hasConcept C71315377 @default.
• W2103576304 hasConcept C71924100 @default.
• W2103576304 hasConceptScore W2103576304C121608353 @default.
• W2103576304 hasConceptScore W2103576304C126322002 @default.
• W2103576304 hasConceptScore W2103576304C126894567 @default.
• W2103576304 hasConceptScore W2103576304C143998085 @default.
• W2103576304 hasConceptScore W2103576304C170493617 @default.
• W2103576304 hasConceptScore W2103576304C2776235491 @default.
• W2103576304 hasConceptScore W2103576304C2777911890 @default.
• W2103576304 hasConceptScore W2103576304C2778468042 @default.
• W2103576304 hasConceptScore W2103576304C2780192828 @default.
• W2103576304 hasConceptScore W2103576304C502942594 @default.
• W2103576304 hasConceptScore W2103576304C61367390 @default.
• W2103576304 hasConceptScore W2103576304C71315377 @default.
• W2103576304 hasConceptScore W2103576304C71924100 @default.
• W2103576304 hasIssue "6" @default.
• W2103576304 hasLocation W21035763041 @default.
• W2103576304 hasLocation W21035763042 @default.
• W2103576304 hasOpenAccess W2103576304 @default.
• W2103576304 hasPrimaryLocation W21035763041 @default.
• W2103576304 hasRelatedWork W1864918391 @default.
• W2103576304 hasRelatedWork W2033566079 @default.
• W2103576304 hasRelatedWork W2071753433 @default.
• W2103576304 hasRelatedWork W2131077462 @default.
• W2103576304 hasRelatedWork W2169608764 @default.
• W2103576304 hasRelatedWork W2327862400 @default.
• W2103576304 hasRelatedWork W2611803138 @default.
• W2103576304 hasRelatedWork W2888003396 @default.
• W2103576304 hasRelatedWork W3111390827 @default.
• W2103576304 hasRelatedWork W4387341186 @default.
• W2103576304 hasVolume "164" @default.
• W2103576304 isParatext "false" @default.
• W2103576304 isRetracted "false" @default.

• next